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Poster Session II S333STAT1-deficient T cells were indeed deficient in Th1 cells
post-BMT. Relative to recipients of WT T cells, recipients of
STAT1-KO T cells had reduced capacity to secrete IFN-g
(46616664 vs. 26566281; p \ 0.03) and TNF-a (31546269 vs.
1872684; p \ 0.001) and reduced absolute numbers of splenic
CD4+IFN-g+ T cells (1461.9 vs .076.02; p \ 0.05) and
CD8+IFN-g+ T cells (4.161.2 vs. 0.86.1; p\0.05). As such, recip-
ients of STAT1-deficient T cells were indeed deficient in Th1-po-
larization post-BMT during cGVHD. Remarkably, relative to WT
T cell recipients, recipients of STAT-1 deficient T cells had in-
creased absolute numbers of post-BMT splenic CD4+IL-176 T
cells (0.260.05 vs 13.266.5.; p\ 0.05). These data indicate that
long-term post-BMT deficiency of Th1-type cells does not protect
against chronic GVHD, perhaps in part due to expansion of alterna-
tive pathogenic T cells such as the Th17 subset.500
THE ROLE OF COMPLEMENT SYSTEM IN THE PATHOGENESIS OF GRAFT
VERSUS HOST DISEASE
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Introduction: Graft-versus-host disease (GVHD) remains a major
cause of morbidity and mortality in bone marrow transplant
(BMT) recipients. GVHD is classically described as T-cell lympho-
cytic infiltration followed by destruction of tissue caused by differ-
ences in HLA. However, treatments aimed at other components of
the immune system have been successful, questioning this paradigm.
The role of the complement system in GVHD is limited. In solid tu-
mor transplantation, activation of the complement system and link to
preformed anti-HLA antibodies in recipients has been associated
with rejection.We describe the evaluation of complement activation
in 53 patients with clinical GVHD in whom40 specimens of skin and
7/13 specimens of colon showed evidence ofGVHDby conventional
histochemical staining method. In addition, we analyzed 11 control
patients with normal colon biopsies. Analysis of complement fixation
was performed using C4d antibody staining method and was
analyzed using the Banff07 grading system where minimal staining
is denoted as positive in\10% of vessels and diffuse staining is pos-
itive in . 50% of vessels. Histology of GVHD was correlated with
C4d deposition. Statistical analysis using Fisher’s exact test was
performed between groups and with controls.
Results: Thirty-four of forty skin biopsies were evaluable for C4d
deposition (6 specimens showing extensive background deposition
were excluded). Twenty-one of thirty-four specimens showed C4d
staining (11 minimal, 9 focal, and 1 diffuse). Twelve of the thirteen
colon biopsies showed C4d staining (2 minimal, 4 focal, and 6 dif-
fuse). Of the 11 control colon biopsies, 10 were negative for C4d
and 1 showed minimal staining. In the cohort that showed clinical
GVHD not pathologically confirmed, 6/6 showed C4d staining.
The difference in C4d staining between the GVHD of the colon
and colon control specimens was statistically significant using
a Fisher’s exact test (p-value 5 0.00000177). In addition, there was
statistical difference between Cd4 staining in clinical GVHD vs.
controls with a p value of 0.0000127.
Conclusion: Our results demonstrate that most patients with clini-
cal GVHD showed vascular staining for C4d. Clinical GVHD and
C4d deposition were closely correlated and statistically different
from controls. This may indicate that C4d positivity is a more
sensitive marker in detecting GVHD of the colon than classic
GVHD histological evaluation.501
SUSTAINED HIGH-DOSE CORTICOSTEROID USE DOES NOT INDEPEN-
DENTLY DIMINISH SURVIVAL AFTER MYELOABLATIVE ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bejanyan, N.1, Lazaryan, A.1, Rybicki, L.2, Tench, S.3, Andresen, S.1,
Sobecks, R.3, Dean, R.3, Pohlman, B.3, Kalaycio, M.3, Bolwell, B.3,
Copelan, E.3 1Taussig Cancer Institute, Cleveland Clinic, Cleveland,
OH; 2Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;
3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHIntroduction: Corticosteroids remain the most efficacious treat-
ment for acute GVHD (aGVHD) following allogeneic hematopoi-
etic stem cell transplantation (AlloHSCT). Some patients with
aGVHD receive high-dose (HD) corticosteroids for $ 2 months
for a variety of reasons. Morbidities related to long term corticoste-
roid use are well recognized, however, the impact of dosing and
treatment duration on survival has not been fully evaluated in the
post-AlloHSCT setting.
Methods: From 1998 to 2009, 272 patients with AlloHSCT were
treated with corticosteroids between post-transplant days 30 and
100 at a single academic institution. Patients in HD group received
$ 30 mg prednisone daily for$ 2 months, whereas those in the low-
dose (LD) corticosteroid group received\ 30 mg at some point in
this interval or $ 30 mg for\ 2 months. Relapse-free (RFS) and
overall survival (OS) were compared between corticosteroid groups.
Cox proportional hazards analysis identified prognostic factors.
Results:HD (n5 98) and LD (n5 174) groups were similar in dis-
tribution of demographic characteristics, comorbidity index, diagno-
sis, number of previous chemotherapies and conditioning regimen
(all p $ 0.3). HD group had more MUD AlloHSCT (p 5 0.05)
and higher-grade aGVHD (p\ 0.001). Malignancy relapse in HD
and LD groups was 24% and 36%, whereas overall mortality was
59% and 55% respectively. Non-relapse mortality tended to be
higher (HR 5 1.5; 95% CI, 1.0-2.3) in HD group. No significant
association was detected between the HD corticosteroid use and
infection-related mortality (p 5 0.1), relapse mortality (p 5 0.2),
RFS (p5 0.8), or OS (p5 0.4). Multivariable analysis of non-relapse
mortality demonstrated no independent prognostic significance of
HD corticosteroid use (HR 5 1.3; 95% CI, 0.8-2) after adjustment
for comorbidity index (HR 5 2 for high vs. low HCT-CI; 95% CI,
0.8-2), source of hematopoietic stem cells (HR 5 2.3 for peripheral
vs. bone marrow; 95%CI, 1.3-4.1) and grade of aGVHD (HR5 1.3
per 1 grade increase; 95% CI, 1.1-1.6).
Conclusions: Using HD corticosteroids for $ 2 months did not
appear to have an independent impact on patient survival following
AlloHSCT and therefore it may be safe to use as necessary for
aGVHD control. The association of HD steroids with non relapse
mortality appears to be related to worse aGVHD.502
THYMIC IRRADIATION IS REQUIRED FOR TRANSPLANTATION TOLER-
ANCE AFTER TLI/ATS NON-MYELOABLATIVE CONDITIONING
Ong, T.1, Van Der Merwe, M.1, Vogel, P.2, Pillai, A.1 1St. Jude Child-
ren’s Research Hospital, Memphis, TN; 2St. Jude Children’s Research
Hospital, Memphis, TN
Total Lymphoid Irradiation and Anti-Thymocyte Serum (TLI/
ATS) conditioning induces potent donor-host tolerance and
GVHD protection via induction of donor CD4+CD25+Foxp3+
Treg after bone marrow transplantation (BMT) (Pillai et al, Blood
2009). Whereas total body irradiation (TBI) at doses as low as 400
cGy associate with lethal acute GVHD after MHC-mismatched
BMT, TLI exposes GVHD target organs to a cumulative radiation
dose of 2400 to 4080 cGy, without GVHD. We investigated the
role of radiation exposure to specific anatomic areas in tolerance in-
duction after TLI/ATS + BMT. Wild-type (WT) BALB/c (H-2d)
hosts received infusion of 50 x 106 bone marrow + 60 x 106 spleno-
cytes from WT C57BL/6 (H-2b) donors (BMT) following 5 doses
of rabbit ATS + 10 doses (240 cGy each2400 cGy total) of fraction-
atedTBI, TLI, or TLIwith lead shielding of specific regions, includ-
ing TLI with focal thymic shielding (TLI-FTS). Day 6 H-
2Kb+CD8+ and H-2Kb+CD4+CD25neg effector cell and H-
2Kb+CD4+Foxp3+ Treg accumulation was quantified in target or-
gans, and GVHD scoring performed on histopathologic sections.
Positive controls included WT BALB/c hosts receiving ATS + sin-
gle-dose 800cGy TBI (PC-1) or ATS + 400 cGy TBI (PC-2) and
50 x 106 bone marrow + 60 x 106 splenocytes from C57BL/6 donors.
Negative controls received 800cGy TBI and 50 x 106 bone marrow
fromWTC57BL/6 (NC-1) or ATS alone + BMT (NC-2). All frac-
tionated TBI hosts died during conditioning with histopathologic
systemic radiation toxicity. In TLI/ATS hosts at day 6 after BMT,
accumulation of H-2Kb+TCR+CD8+ cells was strongly suppressed
in colon, MLN, and spleen (p\0.01), with increased accumulation
of donor Treg (p\0.01) compared to PC-1 controls. Mean colonic
S334 Poster Session IIGVHD scores were: PC-1 (n5 5): 660.7; NC-1 (n5 4): 0; NC-2 (n
5 4): 0; TLI/ATS (n5 4): 0.460.8; TLI-FTS/ATS (n5 7): 4.560.9,
with similar patterns in liver. Day 6 target organ accumulation of
H-2Kb+CD4+Foxp3+ Treg was markedly decreased (p\ 0.05) and
H-2Kb+CD8+ cells increased (p \ 0.01) in TLI-FTS/ATS hosts.
In conclusion, shielding from thymic irradiation alone ablates
tolerance after TLI/ATS + BMT, indicating that recurrent thymic
radiation exposure in the non-myeloablative setting enhances rather
than impedes early immune mechanisms leading to transplantation
tolerance in this regimen.We are currently delineating novel thymic
pathways of enhanced immunoregulatory cell selection in thymic-
irradiation-induced transplant tolerance after TLI/ATS + BMT.503
HOST MYELOID-DERIVED SUPPRESSOR CELLS INDUCE DONOR TREG
PROLIFERATION AND TRANSPLANTATION TOLERANCE VIA IL-4Ra/
STAT6 AFTER TLI/ATS NON-MYELOABLATIVE BMT
Van Der Merwe, M.1, Ong, T.1, Vogel, P.2, Pillai, A.1 1St. Jude Child-
ren’s Research Hospital, Memphis, TN; 2St. Jude Children’s Research
Hospital, Memphis, TN
Murine total Lymphoid Irradiation and rabbit Anti-Thymocyte
Serum (TLI/ATS) non-myeloablative conditioning has been trans-
lated for tolerance induction to facilitate engraftment without lethal
GVHD after allogeneic HSCT.Tolerance is mediated by host IL-4-
induced expansion of donor CD4+Foxp3+ Treg from the unmanipu-
lated graft (Pillai et al, Blood 2009). To delineate mechanisms of
IL-4-dependent donor Treg expansion, wild-type (WT) BALB/c
(H-2d) hosts were given 3 doses ATS + 17 doses (240 cGy each)
TLI and infusion of 50 x 106 bone marrow and 60 x 106 CFSE-la-
beled splenocytes (BMT) from WT or STAT6-/- C57BL/6 (H-2b)
donors. Control WT BALB/c were given 800 cGy single-dose total
body irradiation (TBI) with either 50 x 106 bone marrow alone (neg-
ative control, NC-1) or 50 x 106 bone marrow + 60 x 106 splenocytes
(positive control, PC) from WT C56BL/6 donors. Day 6 H-
2Kb+TCR+CD8+ cell accumulation in spleen, liver and colon were
potently inhibited, and H-2Kb+CD4+Foxp3+ Treg proliferation
maintained, after STAT6-/- donor BMT, indicating that host IL-4
effects on donor Treg proliferation is indirect. By contrast, IL-
4Ra-/- BALB/c hosts receiving TLI/ATS+BMT developed dramatic
lethal acuteGVHD [day 6 colonicGVHDscores: PC (n5 5) 660.8;
NC-1 (n 5 5): 0; WT TLI/ATS (n5 10): 1.3 60.9; IL-4Ra-/-TLI/
ATS (n 5 10): 5.8 61.3]. We delineated 2 subsets of IL-4Ra/
CD124hi cells [CD11b+Gr-1Ghi (M1) and CD11b+Gr-1Gint (M2)]
that dominate the host myeloid compartment in WT hosts at both
day 0 after TLI/ATS and day 6 after TLI/ATS + BMT vs TBI/
ATS or TBI/ATS + BMT (p\ 0.05). Both M1 and M2 subsets are
F4/80negCD115negB220negCD11cnegCD1dhi myeloid derived sup-
pressor cells (MDSC), immature marrow-derived cells which are ab-
lated after lethal or sublethal TBI (p\0.05). H-2Kb-neg M1 and M2
populations sorted from host spleens at day 6 after TLI/ATS +
BMT stimulated H-2Kb+CD4+Foxp3+ Treg but not H-
2Kb+CD4+CD25negFoxp3neg or H-2Kb+CD8+ effector proliferation
in 72-hr CFSE MLR with C57BL/6 splenocyte responders. Day 6
H-2Kb-neg M1 and M2 cells sorted from TLI/ATS + BMT-treated
STAT6-/- or IL-4Ra-/- BALB/c hosts were unable to induce H-
2Kb+CD4+Foxp3+ Treg proliferation in MLR, supporting an IL-4/
STAT6-inducible pathway by which these MDSC gain capacity to
induce Treg proliferation. Using hosts deficient in key IL-4/
STAT6-inducible proteins (Arginase, NOS-2) in MDSC, we are
now delineating the MDSC pathway inducing Treg proliferation
and tolerance after TLI/ATS + BMT.504
HERPES SIMPLEX VIRUS INDUCED STEM CELL DIFFERENTIATION AND
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MARROW TRANSPLANT RECIPIENTS
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Viral pathogens have been implicated in the pathogenesis of
GVHD. Skin rash due to GVHD resembles herpes simplex virus(HSV)-associated erythema multiforme (EM), in which HSV-in-
fected CD34+ stem cells are stimulated to differentiate into antigen
presenting CD1a+ DCs which reside in the skin epidermis and are
known as Langerhans cells (LC). This differentiation involves
increased E-cadherin expression. HSV-primed LCs present HSV
protein to T-cells and lead to EM.
In this prospective study, we examined (1) HSV-induced CD34+
cell differentiation and (2) Expression of the HSV Pol gene in blood
MNC and tissue samples of allogeneic SCT patients obtained before
and after the transplant. HSV prophylaxis was oral acyclovir. Second
skin biopsy was obtained only from patients who developed a rash
posttransplant. Double immunofluorescent staining and FACS anal-
ysis were used to quantify the expression of the HSV antigen (Pol),
CD34 and differentiation-associated markers (e.g., E-cadherin).
A total of 35 patients were enrolled. Data are available in 27 pa-
tients. Twenty-two (81%) had negative pol, CD34/pol, CD14/pol,
CD11b/pol, CD1a/pol immunostaining in the skin at baseline.
Group I: Twelve patients, 7 male, developed GVHD. In this group,
11 (92%) patients became pol+ and 9 had CD34+/pol+ in the skin.
Nine out of 11 (82%) patients had increased number of CD34+/
Pol+ expressing PBMNCs. Seven out of 11 (64%) and 6 out of 7
(86%) patients had increased CD34+/E-cad+ and CD1a+/Pol+
PBMNCs, respectively. Group II: Six patients (22%), all male, devel-
oped rash but no provenGVHD.Only 2 out of 4 patients (50%) with
non-GVHD rash were pol+ in the skin post-SCT. Level of antigen
expression in this group all decreased post-SCT blood samples.
Group III: Eleven patients, 7 of them female, had no rash post-
SCT and all of them remained pol-negative in blood samples
post-transplant. Four patients (36%) had slight increase in CD34+/
Pol+ expressing PBMNCs compared to baseline. CD34+/E-cad+
cells were noted to be minimally increased in 2 patients (18%) only.
In conclusion, our data suggest that HSV can be reactivated at the
cellular level after allogeneic SCT and appears be associated with the
occurrence of skin GVHD. Differentiated LCs in the skin following
HSV infection of the circulating CD34+ cells may well be part of this
association. Additional studies are warranted to confirm these results
and consider new strategies to prevent GVHD, including perhaps
more intense HSV prophylaxis.505
DOUBLE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) RESULTS IN SUCCESSFUL ENGRAFTMENT OF BONE MAR-
ROW FROM BOTH DONORS WITHOUT GRAFT VERSUS HOST OR GRAFT
VERSUS GRAFT EFFECTS
Biswas, C., Sauter, C., Grosso, D., Flomenberg, N., Alpdogan, O. Kimmel
Cancer Center, Thomas Jefferson University, Philadelphia, PA
We hypothesize that the use of two haploidentical donors, each
targeting a different recipient haplotype, will increase anti- leukemia
activity after double haploidentical SCT.We first established a hap-
loidentical transplantmodel using two different hybridmouse strains
as donor and recipient in the experiments. Lethally irradiated
B6CBAF1 (H2Kb/k) recipients were transplanted with T cell de-
pleted (TCD) bone marrow (BM) from B6D2F1 (H2Kb/d) donors.
Recipient mice harvested at days 28, 42 and 84, showed more than
90%donor cell engraftment, including donor derived lymphopoiesis
and myelopoiesis, without evidence of graft versus host disease.
Subsequently, lethally irradiated B6CBAF1 (H2Kb/k) recipients
were transplanted with TCD-BM from two haploidentical donors
(DH model) including B6SJLF1 (H2Kb/s) (donor 1 - D1) and
B6D2F1 (H2Kb/d) (donor 2 - D2). We observed recipients for 90
days and all mice survived without evidence of GVHD or weight
loss. Analyses of blood collected retro-orbitally at day 90 revealed
that recipients of DH transplants had significantly higher WBC
and neutrophil counts than recipients of SH HSCT from either
D1 orD2 respectively. DH recipients consistently showed successful
engraftment with mixed chimerism in both bone marrow and spleen.
We then explored the effects of low dose T cell infusions (1x105) on
chimerism of donor cells. Low doseT cell infusion from eitherD1 or
D2 did not affect the BM cellularity, but did increase the degree of
dominance of that donor’s cells in the BM and spleen.
Recipients of TCDDH transplants were challengedwith P815 tu-
mor cells. We used B6SJLF1 (D1) + B6CBAF1 (D2)/ B6D2F1
model in tumor experiments. Interestingly, recipients of TCD-DH
